{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:22:22Z","timestamp":1747207342173,"version":"3.40.5"},"reference-count":30,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDDT"],"published-print":{"date-parts":[[2021,2,10]]},"abstract":"<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>The goal of this article is to retrace the studies of \u03b2-D-Mannuronic Acid\n(M2000) as a new immunosuppressive drug with non-steroidal anti-inflammatory drugs\n(NSAIDs) property in miscellaneous aspects including in vitro, in vivo examinations, clinical trials\nand related to clinical trials studies. Our goal is to compare the effect of this drug with other\nsimilar drugs through varied researches and to follow tolerability, biocompatibility, potency, safety,\nand efficacy of this medication in different studies, as well as to evaluate its therapeutic effectiveness\nin various diseases.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Materials and Methods:<\/jats:title>\n<jats:p>Different methods were applied in the studies of \u03b2-D-Mannuronic Acid\nunder in vitro, in vivo examinations, and clinical trials phase I, II and III and related investigations\nto these clinical trials using different techniques showing the efficacy of this medication in the\ntreatment of various diseases.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The administration of \u03b2 -D-Mannuronic Acid showed the greatest tolerability and biocompatibility\ncompared to diclofenac, piroxicam, and dexamethasone without or very low side\neffects. The drug has shown a punchy effect on many molecules which participate either in physiologic\nor in pathogenic activities in animal models and human. This new drug not only revealed\nthe anti-inflammatory and immunosuppressive properties but also based on the results of various\ninvestigations, \u03b2-D-Mannuronic Acid showed the antidiabetic, cardioprotective and anti-tumoral\neffects.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>\u03b2-D-Mannuronic Acid (M2000) as a novel immunosuppressive drug with NSAID\nproperties along with antidiabetic, cardioprotective and anti-tumoral efficacy showed great tolerability\nand safety profile. In addition, it has no or mild adverse events compared with many other\nmedicines, therefore this medicament could be considered as a landmark in pharmacology and\nrepresent turn point in the treatment of different diseases based on the experimental and in vitro\nstudies explained and clinical and related studies proved.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1570163817666191227160300","type":"journal-article","created":{"date-parts":[[2019,12,27]],"date-time":"2019-12-27T12:58:37Z","timestamp":1577451517000},"page":"47-57","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["\u03b2-D-Mannuronic Acid (M2000) as a Landmark in Pharmacology"],"prefix":"10.2174","volume":"18","author":[{"given":"Nada A.G.","family":"Gaafar","sequence":"first","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Razavi","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-2747","authenticated-orcid":true,"given":"Abbas","family":"Mirshafiey","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/1570163813666160621120821","volume":"13","author":"Fard N.A.","year":"2016","unstructured":"Fard N.A.; Tabrizian N.; Mirzaei R.; Motamed N.; Zavareh F.T.; Mirshafiey A.; The safety property of \u03b2-D-mannuronic acid (M2000) as a novel immunosuppressive agent on differentiation, maturation and function of human dendritic cells. Curr Drug Discov Technol 2016,13(3),164-169","journal-title":"Curr Drug Discov Technol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/1570163813666161123121952","volume":"14","author":"Tabrizian N.","year":"2017","unstructured":"Tabrizian N.; Fard N.A.; Farazmand A.; Eftekhari R.; Zavareh F.T.; Mirshafiey A.; The biology of \u03b2-D-mannuronic acid (M2000) on human dendritic cell based on microRNA-155 and microRNA-221. Curr Drug Discov Technol 2017,14(1),53-58","journal-title":"Curr Drug Discov Technol"},{"key":"ref=3","author":"Jafarzadeh A.","year":"2018","unstructured":"Jafarzadeh A.; Mortazavi-Jahromi S.S.; Zainodini N.; Mirzaei M.R.; Jafarnezhad-Ansariha F.; Aghazadeh Z.; Mirshafiey A.; Effect of \u03b2-D-Mannuronic Acid (M2000) on oxidativestress enzymes\u2019 gene using healthy donorperipheral blood mononuclear cells for evaluating the anti-aging property. Curr Drug Discov Technol 2018","journal-title":"Curr Drug Discov Technol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.pharep.2017.01.021","volume":"69","author":"Mortazavi-Jahromi S.S.","year":"2017","unstructured":"Mortazavi-Jahromi S.S.; Jamshidi M.M.; Farazmand A.; Aghazadeh Z.; Yousefi M.; Mirshafiey A.; Pharmacological effects of \u03b2-d-mannuronic acid (M2000) on miR-146a, IRAK1, TRAF6 and NF-\u03baB gene expression, as target molecules in inflammatory reactions. Pharmacol Rep 2017,69(3),479-484","journal-title":"Pharmacol Rep"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.pharep.2017.04.015","volume":"69","author":"Mirshafiey A.","year":"2017","unstructured":"Mirshafiey A.; Taeb M.; Mortazavi-Jahromi S.S.; Introduction of \u03b2-d-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property based on COX-1\/COX-2 activity and gene expression. Pharmacol Rep 2017,69(5),1067-1072","journal-title":"Pharmacol Rep"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/sji.12519","volume":"85","author":"Aletaha S.","year":"2017","unstructured":"Aletaha S.; Haddad L.; Roozbehkia M.; M2000 (\u03b2-D-Mannuronic Acid) as a novel antagonist for blocking the TLR2 and TLR4 downstream signalling pathway. Scand J Immunol 2017,85(2),122-129","journal-title":"Scand J Immunol"},{"key":"ref=7","first-page":"443","volume":"16","author":"Farahani MM","year":"2017","unstructured":"Farahani MM; Motevaseli E; Maghsood F; Heidari-Kharaji M; Mirshafiey A;  Anti-inflammatory property of \u03b2-D-mannuronic acid (M2000) on expression and activity of matrix metalloproteinase-2 and -9 through CD147 molecule in phorbol myristate acetatedifferentiated THP-1 Cells 2017,16(5),443-451","journal-title":"Anti-inflammatory property of \u03b2-D-mannuronic acid (M2000) on expression and activity of matrix metalloproteinase-2 and -9 through CD147 molecule in phorbol myristate acetatedifferentiated THP-1 Cells"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.intimp.2017.08.011","volume":"51","author":"Mohammed H.A.","year":"2017","unstructured":"Mohammed H.A.; Saboor-Yaraghi A.A.; Vahedi H.; Yekaninejad M.S.; Panahi G.; Hemmasi G.; Lakzaei M.; Mirshafiey A.; Immunomodulatory effects of M2000 (\u03b2-D-Mannuronic Acid) on TNF-\u03b1, IL-17 and FOXP3 gene expression in patients with inflammatory bowel disease. Int Immunopharmacol 2017,51,107-113","journal-title":"Int Immunopharmacol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.etap.2007.02.002","volume":"24","author":"Mirshafiey A.","year":"2007","unstructured":"Mirshafiey A.; Rehm B.; Abhari R.S.; Borzooy Z.; Sotoude M.; Razavi A.; Production of M2000 (\u03b2-d-mannuronic acid) and its therapeutic effect on experimental nephritis. Environ Toxicol Pharmacol 2007,24(1),60-66","journal-title":"Environ Toxicol Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1111\/j.1365-3083.2005.01594.x","volume":"61","author":"Mirshafiey A.","year":"2005","unstructured":"Mirshafiey A.; Cuzzocrea S.; Rehm B.; Mazzon E.; Saadat F.; Sotoude M.; Treatment of experimental arthritis with M2000, a novel designed non-steroidal anti-inflammatory drug. Scand J Immunol 2005,61(5),435-441","journal-title":"Scand J Immunol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1111\/1440-1681.12907","volume":"45","author":"Rastegari-Pouyani M.","year":"2018","unstructured":"Rastegari-Pouyani M.; Mostafaie A.; Mansouri K.; Mortazavi-Jahromi S.S.; Mohammadi-Motlagh H.R.; Mirshafiey A.; Anti-angiogenesis effect of \u03b2-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive properties under experimental model. Clin Exp Pharmacol Physiol 2018,45(4),370-376","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1080\/08923973.2018.1455209","volume":"40","author":"Mortazavi-Jahromi S.S.","year":"2018","unstructured":"Mortazavi-Jahromi S.S.; Alizadeh S.; Javanbakht M.H.; Mirshafiey A.; Cardioprotective effect of \u03b2-D-Mannuronic Acid (M2000) as a novel NSAID on gene expression of oxLDL scavenger receptors in the experimental diabetic model. Immunopharmacol Immunotoxicol 2018,40(4),284-289","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1080\/13813455.2018.1481094","volume":"125","author":"Mortazavi-Jahromi SS","year":"2019","unstructured":"Mortazavi-Jahromi SS; Alizadeh S; Javanbakht MH; Mirshafiey A; Anti-diabetic effect of \u03b2-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on insulin production, blood glucose, and inflammatory markers in the experimental diabetes model. Archives of physiology and biochemistry 2019,125(5),435-440","journal-title":"Archives of physiology and biochemistry"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1177\/1533317516678086","volume":"32","author":"Athari Nik Azm S.","year":"2017","unstructured":"Athari Nik Azm S.; Vafa M.; Sharifzadeh M.; Safa M.; Barati A.; Mirshafiey A.; Effects of M2000 (D-mannuronic acid) on learning, memory retrieval, and associated determinants in a rat model of Alzheimer\u2019s disease. Am J Alzheimer\u2019s Dis Other  Dementias\u00ae 2017,32(1),12-21","journal-title":"Am J Alzheimer\u2019s Dis Other  Dementias\u00ae"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1515\/jbcpp-2016-0092","volume":"28","author":"Hosseini S.","year":"2017","unstructured":"Hosseini S.; Abdollahi M.; Azizi G.; Anti-aging effects of M2000 (\u03b2-D-mannuronic acid) as a novel immunosuppressive drug on the enzymatic and non-enzymatic oxidative stress parameters in an experimental model. J Basic Clin Physiol Pharmacol 2017,28(3),249-255","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"ref=16","first-page":"1","volume":"62","author":"Hajivalili M.","year":"2016","unstructured":"Hajivalili M.; Pourgholi F.; Majidi J.; G2013 modulates TLR4 signaling pathway in IRAK-1 and TARF-6 dependent and miR-146a independent manner. Cell Mol Biol 2016,62(4),1-5","journal-title":"Cell Mol Biol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3109\/08923973.2015.1113296","volume":"37","author":"Fattahi M.J.","year":"2015","unstructured":"Fattahi M.J.; Abdollahi M.; Agha Mohammadi A.; Preclinical assessment of \u03b2-D-Mannuronic Acid (M2000) as a non-steroidal anti-inflammatory drug. Immunopharm Immunother 2015,37,535-540","journal-title":"Immunopharm Immunother"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/cam4.1013","volume":"6","author":"Hosseini F.","year":"2017","unstructured":"Hosseini F.; Hassannia H.; Mahdian-Shakib A.; Jadidi-Niaragh F.; Enderami S.E.; Fattahi M.; Anissian A.; Mirshafiey A.; Kokhaei P.; Targeting of crosstalk between tumor and tumor microenvironment by \u03b2-D mannuronic acid (M2000) in murine breast cancer model. Cancer Med 2017,6(3),640-650","journal-title":"Cancer Med"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.intimp.2017.11.003","volume":"54","author":"Fattahi M.J.","year":"2018","unstructured":"Fattahi M.J.; Jamshidi A.R.; Mahmoudi M.; Vojdanian M.; Yekaninejad M.S.; Jafarnezhad-Ansariha F.; Ahmadi H.; Rehm B.H.; Matsuo H.; Cuzzocrea S.; Hosseini M.; Evaluation of the efficacy and safety of \u03b2-d-mannuronic acid in patients with ankylosing spondylitis: a 12-week randomized, placebo-controlled, phase I\/II clinical trial. Int Immunopharmacol 2018,54,112-117","journal-title":"Int Immunopharmacol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10787-018-0475-z","volume":"26","author":"Ahmadi H.","year":"2018","unstructured":"Ahmadi H.; Jamshidi A.R.; Gharibdoost F.; A phase I\/II randomized, controlled, clinical trial for assessment of the efficacy and safety of \u03b2-D-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology 2018,26(3),737-745","journal-title":"Inflammopharmacology"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s10787-018-00557-2","volume":"27","author":"Rezaieyazdi Z.","year":"2019","unstructured":"Rezaieyazdi Z.; Farooqi A.; Soleymani-Salehabadi H.; Ahmadzadeh A.; Aslani M.; Omidian S.; Sadoughi A.; Vahidi Z.; Khodashahi M.; Zamurrad S.; Mortazavi-Jahromi S.S.; International multicenter randomized, placebo-controlled phase III clinical trial of \u03b2-d-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology 2019,27(5),911-921","journal-title":"Inflammopharmacology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.intimp.2017.08.018","volume":"52","author":"Roozbehkia M.","year":"2017","unstructured":"Roozbehkia M.; Mahmoudi M.; Aletaha S.; Rezaei N.; Fattahi M.J.; Jafarnezhad-Ansariha F.; Barati A.; Mirshafiey A.; The potent suppressive effect of \u03b2-d-mannuronic acid (M2000) on molecular expression of the TLR\/NF-kB signaling pathway in ankylosing spondylitis patients. Int Immunopharmacol 2017,52,191-196","journal-title":"Int Immunopharmacol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.biopha.2018.02.059","volume":"100","author":"Fattahi M.J.","year":"2018","unstructured":"Fattahi M.J.; Ahmadi H.; Jafarnezhad-Ansariha F.; Mortazavi-Jahromi S.S.; Rehm B.H.; Cuzzocrea S.; Matsuo H.; Mirshafiey A.; Oral administration effects of \u03b2-d-mannuronic acid (M2000) on Th17 and regulatory T cells in patients with ankylosing spondylitis. Biomed Pharmacother 2018,100,495-500","journal-title":"Biomed Pharmacother"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10787-017-0386-4","volume":"26","author":"Jafarnezhad-Ansariha F.","year":"2018","unstructured":"Jafarnezhad-Ansariha F.; Yekaninejad M.S.; Jamshidi A.R.; The effects of \u03b2-D-mannuronic acid (M2000), as a novel NSAID, on COX1 and COX2 activities and gene expression in ankylosing spondylitis patients and the murine monocyte\/macrophage, J774 cell line. Inflammopharmacology 2018,26(2),375-384","journal-title":"Inflammopharmacology"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10787-017-0410-8","volume":"26","author":"Ahmadi H.","year":"2018","unstructured":"Ahmadi H.; Mahmoudi M.; Gharibdoost F.; Targeting of circulating Th17 cells by \u03b2-D-mannuronic acid (M2000) as a novel medication in patients with rheumatoid arthritis. Inflammopharmacology 2018,26(1),57-65","journal-title":"Inflammopharmacology"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s10787-018-0475-z","volume":"26","author":"Ahmadi H.","year":"2018","unstructured":"Ahmadi H.; Jamshidi A.R.; Gharibdoost F.; Mahmoudi M.; Rastkari N.; Mostafaei S.; Fattahi M.J.; Vojdanian M.; Cuzzocrea S.; Rehm B.H.; Matsuo H.; A phase I\/II randomized, controlled, clinical trial for assessment of the efficacy and safety of \u03b2-d-mannuronic acid in rheumatoid arthritis patients. Inflammopharmacology 2018,26(3),737-745","journal-title":"Inflammopharmacology"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2174\/1574884712666170605101845","volume":"12","author":"Vojdanian M.","year":"2017","unstructured":"Vojdanian M.; Ahmadi H.; Jamshidi A.R.; The anti-migraine effects of M2000 (\u03b2-D-Mannuronic Acid) on a patient with rheumatoid arthritis: case report. Curr Clin Pharmacol 2017,12(2),127-130","journal-title":"Curr Clin Pharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2174\/1570163814666170321113059","volume":"14","author":"Ahmadi H.","year":"2017","unstructured":"Ahmadi H.; Jamshidi A.R.; Mahmoudi M.; The potent inhibitory effect of \u03b2-D-mannuronic acid (M2000) as a novel NSAID with immunosuppressive property on anti-cyclic citrullinated peptide antibodies, rheumatoid factor and anti-dsDNA antibodies in patients with rheumatoid arthritis. Curr Drug Discov Technol 2017,14(3),206-214","journal-title":"Curr Drug Discov Technol"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.2147\/DDDT.S129419","volume":"3011","author":"Barati A.","year":"2017","unstructured":"Barati A.; Jamshidi A.R.; Ahmadi H.; Aghazadeh Z.; Mirshafiey A.; A effects of \u03b2-D-mannuronic acid, as a novel non-steroidal anti-inflammatory medication within immunosuppressive properties, on IL17, ROR\u03b3t, IL4 and GATA3 gene expressions in rheumatoid arthritis patients. Drug Des Devel Ther 2017,3011,1027-1033","journal-title":"Drug Des Devel Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"530","DOI":"10.2174\/1871530318666180418111354","volume":"18","author":"Jahanbakhshi M.","year":"2018","unstructured":"Jahanbakhshi M.; Babaloo Z.; Mortazavi-Jahromi S.S.; Shokri M.M.; Ahmadi H.; Mirshafiey A.; Modification of sexual hormones in rheumatoid arthritis patients by M2000 (\u03b2-D-mannuronic Acid) as a novel NSAID with immunosuppressive property. Endocr Metab Immune Disord Drug Targets 2018,18(5),530-536","journal-title":"Endocr Metab Immune Disord Drug Targets"}],"container-title":["Current Drug Discovery Technologies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/177876","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/177876\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/177876","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T12:43:52Z","timestamp":1640177032000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/177876\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,10]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1570163817666191227160300","relation":{},"ISSN":["1570-1638"],"issn-type":[{"type":"print","value":"1570-1638"}],"subject":[],"published":{"date-parts":[[2021,2,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-08-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-10-12","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}